Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de los sellos TRE en sujetos postoperatorios tempranos

9 de noviembre de 2026 actualizado por: Hollister Incorporated

Estudio de sellos TRE en sujetos postoperatorios tempranos

This study will evaluate two Ostomy Seals/Rings in a group of post-operative patients.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Estimado)

107

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: John Whitaker; Chief Investigator
  • Número de teléfono: 27148 024 7696 7148
  • Correo electrónico: John.Whitaker@uhcw.nhs.uk

Ubicaciones de estudio

    • County Durham
      • Stockton-on-Tees, County Durham, Reino Unido, TS19 8PE
        • Reclutamiento
        • North Tees University Hospital
        • Contacto:
    • East Sussex
      • Saint Leonards-on-Sea, East Sussex, Reino Unido, TN37 7RD
        • Reclutamiento
        • East Sussex Healthcare NHS Trust: Conquest and Eastbourne Hospitals
        • Contacto:
    • Kent
      • Ashford, Kent, Reino Unido, TN24 0LZ
        • Reclutamiento
        • William Harvey Hospital
        • Contacto:
      • Margate, Kent, Reino Unido, CT9 4AN
        • Reclutamiento
        • Queen Elizabeth The Queen Mother Hospital
        • Contacto:
    • North Yorkshire
      • Middlesbrough, North Yorkshire, Reino Unido, TS4 3BW
        • Reclutamiento
        • South Tees University Hospital
        • Contacto:
    • Surrey
      • Redhill, Surrey, Reino Unido, RH1 5RH
        • Reclutamiento
        • East Surrey Hospital
        • Contacto:
    • West Midlands
      • Coventry, West Midlands, Reino Unido, CV2 2DX
        • Reclutamiento
        • University Hospital Coventry
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. At least 18 years of age
  2. Has their ostomy surgery and post-operative care in the United Kingdom (UK)
  3. Has a colostomy, ileostomy, or urostomy and no reversal planned during the study evaluation period
  4. Able to have first study product applied at first pouch change after surgery (or up to 4 days post-op)
  5. Is appropriate to use a barrier seal per the Investigator
  6. Able to provide an informed consent for study participation
  7. Willing to follow protocol procedures, including participating in study visits, as demonstrated by signing the informed consent

Exclusion Criteria:

  1. Is over 85 years of age
  2. Has received chemotherapy or radiation in the past 30 days or reports beginning chemotherapy or radiation during the study.
  3. A score of 1, 2, or 3 for any of the three OCSI Tool PSC-related domains (i.e., peristomal irritant dermatitis, peristomal bleeding, and hyperplasia) at time of enrollment
  4. Has a fistula in the peristomal area at time of enrollment
  5. Has an open draining wound (not including mucocutaneous separation) in the peristomal area at time of enrollment
  6. Has a suspected infection in the peristomal area at time of enrollment
  7. Is pregnant or lactating at time of enrollment (as determined by interview only)
  8. Is unable to speak, read, and understand English.
  9. Is currently participating in another clinical study using ostomy products
  10. Is currently an employee of Hollister Incorporated or any ostomy manufacturer

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Un Sello de Ostomía

An absorptive ostomy seal

Comparador activo: Un Anillo de Ostomía

The Ostomy Ring contains Aloe

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The Risk of Peristomal Skin Complications (PSCs) as measured using the three PSC-related questions on the Ostomy Complication Severity Index (OCSI)
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

The three PSC-related questions on the Ostomy Complication Severity Index (OCSI) are related to peristomal irritant dermatitis, peristomal bleeding, and hyperplasia. Each of these three items is rated on a scale of 0-3, with 0 indicating absence of the condition, and 3 indicating the condition is severe.

From enrollment to the end of treatment at 9 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Total Ostomy Complication Severity Index (OCSI) score and six stomal complication (non-PSC) domains of the OCSI and associated severity
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Each of the OCSI items are scored on a scale of 0-3, with 0 indicating absence of the condition and 3 indicating the condition is severe.

From enrollment to the end of treatment at 9 weeks
Mediation of peristomal skin complications (PSCs) by leakage absorption measured using the leakage item on the Ostomy Complication Severity Index (OCSI)
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

The leakage item on the OCSI has a scale of 0 (no leakage) to 3 (leakage approximately 1-2 times per day)

From enrollment to the end of treatment at 9 weeks
Visible moisture/effluent on peristomal skin under the study seal area (OCSI Supplementary Question)
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Assessed only if leakage is reported in the OCSI tool (conditional). Responses: Great amount / Slight amount / None (ordinal categorical).

From enrollment to the end of treatment at 9 weeks
Seal absorption of moisture/effluent under the study seal area (OCSI Supplementary Question)
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Participant response to whether the study seal absorbed moisture/effluent from around the stoma/peristomal skin under the seal. Responses: Yes / Somewhat / No, not at all (ordinal categorical).

From enrollment to end of treatment at 9 weeks
Presence of peristomal skin conditions (OCSI Supplementary Question)
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Checklist of skin conditions present: burning, itching, maceration, fungal rash, folliculitis, granuloma, mechanical trauma, product sensitivity/allergy, pyoderma gangrenosum, other, none.

From enrollment to end of treatment at 9 weeks
Peristomal skin burning severity (OCSI Supplementary Question)
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Rated on a numeric scale from 0 (absent) to 10 (worst burning imaginable). Assessed only if burning is reported (conditional logic from Q25). Higher scores indicate worse burning.

From enrollment to end of treatment at 9 weeks
Peristomal skin itching severity (OCSI Supplementary Question)
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Rated on a numeric scale from 0 (absent) to 10 (worst itching imaginable). Assessed only if itching is reported (conditional logic from Q25). Higher scores indicate worse itching.

From enrollment to end of treatment at 9 weeks
Time to resolution of peristomal skin complications (PSCs), assessed by the Ostomy Complication Severity Instrument (OCSI) at visits and adverse event (AE) reports between visits
Periodo de tiempo: From first PSC onset to resolution through end of treatment at 9 weeks

Unit of Measure: days

From first PSC onset to resolution through end of treatment at 9 weeks
Time to recurrence of peristomal skin complications (PSCs) after resolution, assessed by the OCSI at visits and AE reports between visits
Periodo de tiempo: From PSC resolution to first recurrence through end of treatment at 9 weeks

Unit of Measure: days

From PSC resolution to first recurrence through end of treatment at 9 weeks
Proportion of participants with PSC occurrence, PSC resolution, and PSC recurrence, assessed by the OCSI at visits and AE reports between visits
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Unit of Measure: percent (%)

From enrollment to end of treatment at 9 weeks
Patient satisfaction with the study Seal/Ring assessed using the Study-Specific Patient Satisfaction Questionnaire (Likert scale)
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied)

From enrollment to the end of treatment at 9 weeks
Clinician Satisfaction with the study Seal/Ring assessed using the Study-Specific Clinician Satisfaction Questionnaire (Likert scale)
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied)

From enrollment to the end of treatment at 9 weeks
Ability to correctly use the seal/ring with available instructional resources, assessed by the Study-Specific Instructional Resources Question
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Single study-specific question assessing whether instructional resources (e.g., IFU, online guides) enabled correct use of the seal/ring; responses: Yes / No / Did not use instructional resources. Results will be reported as the proportion of participants in each response category.

From enrollment to the end of treatment at 9 weeks
Seal swelling/expansion incidence, assessed by Study-Specific Swell/Expand Question
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Participant response comparing seal size at application versus at barrier change. Responses: No, seal did not swell/expand / Yes, seal swelled/expanded.

From enrollment to the end of treatment at 9 weeks
Effectiveness of seal swelling/expansion for secure fit against leakage, assessed by Study-Specific Swell/Expand Question
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Participant response regarding whether swelling/expansion provided a better, more secure fit against leakage. Responses: No, not at all / Yes, somewhat / Yes, definitely (ordinal categorical).

From enrollment to end of treatment at 9 weeks
Perceived moisture-wicking effect, assessed by the Study-Specific Moisture-Wicking Question (3-point scale)
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Single study-specific question assessing perceived moisture-wicking away from peristomal skin. Responses: No, not at all / Yes, somewhat / Yes, definitely.

From enrollment to the end of treatment at 9 weeks
Clinician agreement with the study Seal/Ring performance assessed using the Study-Specific Clinician Agreement Questionnaire (Likert scale)
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Strongly agree) to 5 (Strongly disagree)

From enrollment to the end of treatment at 9 weeks
Quantity of seals/rings, barriers, and accessories used, assessed by Study-Specific Resource Utilization Log
Periodo de tiempo: From enrollment to the end of treatment at 9 weeks

Unit of measure: mean/median number used per participant (counts)

From enrollment to the end of treatment at 9 weeks
Wear/use time (longevity) of seals/rings and barriers, assessed by Study-Specific Resource Utilization Log
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Unit of measure: hours or days of wear time per application (time)

From enrollment to end of treatment at 9 weeks
Peristomal skin-related unplanned healthcare visits, assessed by Study-Specific Healthcare Utilization Question
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Unit of measure: number of visits per participant; optionally proportion with ≥1 visit (counts/%)

From enrollment to end of treatment at 9 weeks
Total ostomy seal/ring costs, derived from quantities recorded in the Resource and Healthcare Utilization Logs
Periodo de tiempo: From enrollment to end of treatment at 9 weeks

Unit of measure: currency (e.g., dollars)

From enrollment to end of treatment at 9 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: John Whitaker, University Hospital Coventry

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de junio de 2026

Finalización primaria (Estimado)

1 de marzo de 2027

Finalización del estudio (Estimado)

1 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

25 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de marzo de 2026

Publicado por primera vez (Actual)

10 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 6042-OST

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir